• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Urinary System Drugs Endocrine System Other
  • Pharmaceutical IntermediatesPharmaceutical intermediates Heterocyclic Compound OLED material intermediate Diphenylamine intermediates Nutritional Supplements Pharmaceutical raw materials
  • Medicine ExcipientsFiller Solubilizers Coating material Disintegrant Excipient Iubricant Other
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Gastrointestinal Drugs Disinfectant Anthelmintics Antiviral drugs Sow health care Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Organic intermediates Carbidopa Powder 38821-49-7

    • Organic intermediates Carbidopa Powder 38821-49-7
    • Organic intermediates Carbidopa Powder 38821-49-7 storehouse
    • Organic intermediates Carbidopa Powder 38821-49-7 quality testing
    • Organic intermediates Carbidopa Powder 38821-49-7 quality testing
    • Organic intermediates Carbidopa Powder 38821-49-7 certificate

    Product Overview:

    Carbidopa is a strong peripheral dopa decarboxylase inhibitor.
    It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.
    Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.

    Organic intermediates Carbidopa Powder 38821-49-7 Attributes

    Organic intermediates Carbidopa Powder 38821-49-7

    CAS:38821-49-7

    MF:C10H16N2O5

    Carbidopa

    MW:244.25

    EINECS:642-905-9

    Specification: 99% min Carbidopa Powder

    Sample: Carbidopa Powder

    Packaging:1kg/bag, 25kg/drum

    Brand: Henrikang

    Appearance: White powder

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Organic intermediates Carbidopa Powder 38821-49-7 Details

    Carbidopa Powder Usage and Synthesis.

    Carbidopa is a strong peripheral dopa decarboxylase inhibitor.

    It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.

    Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.

    Carbidopa Powder

    Uses of Carbidopa.

    Carbidopa is a strong peripheral dopa decarboxylase inhibitor.

    It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.

    Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.

    Carbidopa

    Pharmacological Effect of Carbidopa.

    Carbidopa is a peripheral decarboxylase inhibitor, not easy to enter the centre, only inhibit the conversion of peripheral levodopa to dopamine, so that the circulating levodopa content increases, and thus the amount of levodopa into the centre increases, levodopa is converted into dopamine by dopamine decarboxylase in the brain to play a pharmacological role in improving the symptoms of tremor paralysis.

    Carbidopa CAS 38821-49-7

    Note of  Bulk Carbidopa Powder.

    1, hypertension, arrhythmia, diabetes mellitus patients with caution.

    2、Patients with osteoporosis should resume normal activities slowly to reduce the risk of fracture.

    3、Blood test, liver and kidney function and electrocardiogram should be checked during the use of the drug.

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,